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Introduction. New treatment techniques based on intensitymodulated (IMRT) improve the conformation of the dose distribution to
the target volume, minimizing the absorbed dose in the organs at risk Due to the complexity of these techniques a pretreatment
patient-speciﬁc quality control is necessary.
Purpose. To implement a quality control procedure to ensure the agreement between the planned and the delivered treatment.
Materials and methods. In our company there are available 2 Varian CLINAC 21EX accelerators and 1 Xio (Elekta) treatment planning
system (TPS) To verify the absorbed dose, the treatment plan is calculated based on computed tomography (CT) images of
the phantom I’mRT (Scanditronix-Wellhofer). After irradiating the treatment plan on the phantom, the measured dose at the
isocenter is compared with the calculated dose from TPS using a 3D ionization camera PinPoint 0016 cc (PTW31016). A portal
imaging device, EPID, (Portal Vision AS1000) is used to check the dose distribution. The treatment plan is calculated on the CT of
the EPID and an integrated image of each beam is obtained. The correspondence between the pixel values and the dose is known
by prior calibration of the EPID. Comparison between the measured dose distribution and the dose calculated from TPS is made
with the software OmniPro I’mRT (IbaDosimetry).
Results. The discrepancy between the dose measured by ionization chamber and the calculated dose should be less than ±3%
for the acceptance of the treatment. The dosimetric distributions were evaluated using gamma analysis. Treatments are only
accepted with gamma test results (3%, 3mm) <1 higher than 95%.
Conclusions. The procedure used for treatment veriﬁcation has proved to be accurate, fast and simple. Moreover, EPID-based
dosimetry allows immediate analysis of the results and presents the additional advantage of allowing separate evaluation of
each beam’s dose distribution.
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Introduction. Craniospinal irradiation for children with neural cancer diseases or carcinomas is a very important technique in pae-
diatric radiotherapy. Treatment in prone position is more appropriate, although requires special immobilisation system adapted
for children. The aim of our study is to present a clinical experience of one paediatric treatment using this new immobilisation
system and veriﬁcation of treatment positioning.
Objects. Positioning tracking and veriﬁcation of union ﬁeld dosimetric.
Methods. A 3 y.o. patient diagnosed with choroid plexus carcinoma of the left occipital, GRADE III, with complete exerisis,
chemotherapy (CPT protocol SIOP 2009). Radiotherapy treatment: prescribed dose, 30.6Gy, (1.8Gy/F) with a boost to the PTV
up to 54Gy. Treatment was delivered in a Primus Linac with a spinal posterior beam and two lateral cranial beams, changing
every 10Gy the junction point of the beams to reduce overdoses, opening the spinal ﬁeld 1 cm and closing cranial to adapt and
matching them. A newly designed pediatric immobilizer adaptable for ages 2–15 years (by SIHO) was used to immobilize the
patient. Gafchromics® ﬁlms were used to verify the doses in the overlapping areas, using solid water. Treatment positioning was
verify by Exact Trac® (Brainlab).
Results. Differences between measured doses by Gafchromic ﬁlms and calculated doses by TPS Xio® in junction points were lower
than 4%, which decreases to 1.3% of 10Gy to change the ﬁeld junction area. With Exac Trac® system movements of the patient
are measured in inter-fractions and intra-fraction. The movements of the centre of the tree-ball device are lesser than 1mm for
intrafraction measurements, and lesser than 5mm for interfracion measurements.
Conclusions. The new immobilisation system allows a reproducible positioning of the patient during the treatment. The combined
use of this immobilisation system with the ExacTract monitoring system reduces the intrafraction positioning inaccuracy to
1mm, as other much more expensive systems.
http://dx.doi.org/10.1016/j.rpor.2013.03.631
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Introduction and objective. A new system based in structured visible light has been installed in our service that allows to reconstruct
the three dimensional patient surface. We want to show how it works and what possibilities offers for patient treatment.
